CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Ocular Therapeutix Inc - OCUL CFD

    3.59
    2.97%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Ocular Therapeutix Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 3.7
    Open* 3.67
    1-Year Change* 31.54%
    Day's Range* 3.5 - 3.7
    52 wk Range 2.00-7.96
    Average Volume (10 days) 980.53K
    Average Volume (3 months) 16.74M
    Market Cap 173.93M
    P/E Ratio -100.00K
    Shares Outstanding 79.42M
    Revenue 57.72M
    EPS -0.87
    Dividend (Yield %) N/A
    Beta 1.03
    Next Earnings Date Mar 4, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 3.59 -0.07 -1.91% 3.66 3.71 3.48
    Dec 7, 2023 3.70 0.11 3.06% 3.59 3.87 3.49
    Dec 6, 2023 3.60 0.04 1.12% 3.56 3.94 3.50
    Dec 5, 2023 3.55 0.22 6.61% 3.33 3.63 3.23
    Dec 4, 2023 3.34 0.48 16.78% 2.86 3.52 2.85
    Dec 1, 2023 2.66 0.20 8.13% 2.46 2.66 2.41
    Nov 30, 2023 2.46 -0.09 -3.53% 2.55 2.72 2.43
    Nov 29, 2023 2.53 0.21 9.05% 2.32 2.58 2.29
    Nov 28, 2023 2.27 0.09 4.13% 2.18 2.27 2.14
    Nov 27, 2023 2.20 0.02 0.92% 2.18 2.22 2.12
    Nov 24, 2023 2.21 0.03 1.38% 2.18 2.27 2.18
    Nov 22, 2023 2.20 0.00 0.00% 2.20 2.28 2.17
    Nov 21, 2023 2.17 -0.11 -4.82% 2.28 2.34 2.16
    Nov 20, 2023 2.33 0.13 5.91% 2.20 2.39 2.20
    Nov 17, 2023 2.25 0.22 10.84% 2.03 2.28 2.03
    Nov 16, 2023 2.05 -0.14 -6.39% 2.19 2.19 2.04
    Nov 15, 2023 2.23 0.13 6.19% 2.10 2.36 2.10
    Nov 14, 2023 2.18 -0.13 -5.63% 2.31 2.35 2.07
    Nov 13, 2023 2.19 0.15 7.35% 2.04 2.23 2.00
    Nov 10, 2023 2.08 -0.04 -1.89% 2.12 2.18 1.98

    Ocular Therapeutix Inc Events

    Time (UTC) Country Event
    Monday, March 4, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Ocular Therapeutix Inc Earnings Release
    Q4 2023 Ocular Therapeutix Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 51.494 43.522 17.403 4.227 1.99
    Revenue 51.494 43.522 17.403 4.227 1.99
    Cost of Revenue, Total 4.54 4.406 2.083 2.325 0.465
    Gross Profit 46.954 39.116 15.32 1.902 1.525
    Total Operating Expense 130.148 121.559 80.25 90.029 61.108
    Selling/General/Admin. Expenses, Total 72.146 67.07 49.473 46.613 23.728
    Research & Development 53.462 50.083 28.694 41.091 36.915
    Operating Income -78.654 -78.037 -62.847 -85.802 -59.118
    Interest Income (Expense), Net Non-Operating 7.617 71.483 -92.789 -0.562 -0.86
    Other, Net -0.001 0.001 -0.008 0
    Net Income Before Taxes -71.038 -6.553 -155.636 -86.372 -59.978
    Net Income After Taxes -71.038 -6.553 -155.636 -86.372 -59.978
    Net Income Before Extra. Items -71.038 -6.553 -155.636 -86.372 -59.978
    Net Income -71.038 -6.553 -155.636 -86.372 -59.978
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -71.038 -6.553 -155.636 -86.372 -59.978
    Income Available to Common Incl. Extra. Items -71.038 -6.553 -155.636 -86.372 -59.978
    Diluted Net Income -71.038 -6.553 -155.636 -86.372 -59.978
    Diluted Weighted Average Shares 76.875 76.3929 60.7522 45.2732 38.1151
    Diluted EPS Excluding Extraordinary Items -0.92407 -0.08578 -2.56182 -1.90779 -1.5736
    Diluted Normalized EPS -0.92407 -0.08578 -2.56182 -1.90779 -1.5736
    Total Extraordinary Items 0 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 15.186 13.374 14.075 11.965 12.266
    Revenue 15.186 13.374 14.075 11.965 12.266
    Cost of Revenue, Total 1.304 1.214 1.012 1.073 1.155
    Gross Profit 13.882 12.16 13.063 10.892 11.111
    Total Operating Expense 35.756 35.923 33.436 33.509 32.182
    Selling/General/Admin. Expenses, Total 19.358 19.962 18.881 18.717 17.927
    Research & Development 15.094 14.747 13.543 13.719 13.1
    Operating Income -20.57 -22.549 -19.361 -21.544 -19.916
    Interest Income (Expense), Net Non-Operating -0.112 -7.768 3.819 -2.645 1.15
    Net Income Before Taxes -20.682 -30.318 -15.542 -24.188 -18.766
    Net Income After Taxes -20.682 -30.318 -15.542 -24.188 -18.766
    Net Income Before Extra. Items -20.682 -30.318 -15.542 -24.188 -18.766
    Net Income -20.682 -30.318 -15.542 -24.188 -18.766
    Income Available to Common Excl. Extra. Items -20.682 -30.318 -15.542 -24.188 -18.766
    Income Available to Common Incl. Extra. Items -20.682 -30.318 -15.542 -24.188 -18.766
    Diluted Net Income -20.682 -30.318 -15.542 -24.188 -18.766
    Diluted Weighted Average Shares 78.0477 77.3863 77.0118 76.9758 76.7643
    Diluted EPS Excluding Extraordinary Items -0.26499 -0.39177 -0.20181 -0.31423 -0.24446
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.26499 -0.39177 -0.20181 -0.31423 -0.24446
    Other, Net 0 -0.001 0 0.001 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 129.627 191.3 246.16 60.17 56.193
    Cash and Short Term Investments 102.3 164.164 228.057 54.437 54.062
    Cash & Equivalents 102.3 164.164 228.057 54.437 54.062
    Short Term Investments
    Total Receivables, Net 21.325 21.135 12.252 2.548 0.201
    Accounts Receivable - Trade, Net 21.325 21.135 12.252 2.548 0.201
    Total Inventory 1.974 1.25 1.201 0.954 0.217
    Prepaid Expenses 4.028 4.751 4.65 2.231 1.713
    Total Assets 149.289 204.887 261.863 78.74 73.043
    Property/Plant/Equipment, Total - Net 17.898 11.823 13.939 16.806 10.236
    Property/Plant/Equipment, Total - Gross 35.176 27.03 26.725 26.825 17.863
    Accumulated Depreciation, Total -17.278 -15.207 -12.786 -10.019 -7.627
    Other Long Term Assets, Total 1.764 1.764 1.764 1.764 6.614
    Total Current Liabilities 31.395 26.337 26.664 12.029 9.159
    Accounts Payable 5.123 4.592 2.709 3.268 2.965
    Accrued Expenses 25.696 21.745 15.665 8.761 6.194
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 8.29 0
    Other Current Liabilities, Total 0.576
    Total Liabilities 113.91 116.888 185.768 82.37 37.168
    Total Long Term Debt 54.006 51.435 41.243 49.312 24.788
    Long Term Debt 54.006 51.435 41.243 49.312 24.788
    Other Liabilities, Total 28.509 39.116 117.861 21.029 3.221
    Total Equity 35.379 87.999 76.095 -3.63 35.875
    Redeemable Preferred Stock 0 0
    Common Stock 0.008 0.008 0.008 0.005 0.004
    Additional Paid-In Capital 652.213 633.795 615.338 379.98 333.114
    Retained Earnings (Accumulated Deficit) -616.842 -545.804 -539.251 -383.615 -297.243
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 149.289 204.887 261.863 78.74 73.043
    Total Common Shares Outstanding 77.2018 76.7319 75.9967 50.3336 41.5181
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 141.258 100.712 107.162 129.627 145.615
    Cash and Short Term Investments 110.55 66.606 79.026 102.3 120.95
    Cash & Equivalents 110.55 66.606 79.026 102.3 120.95
    Total Receivables, Net 23.589 27.309 21.124 21.325 19.802
    Accounts Receivable - Trade, Net 23.589 27.309 21.124 21.325 19.802
    Total Inventory 2.257 2.204 2.266 1.974 1.545
    Prepaid Expenses 4.862 4.593 4.746 4.028 3.318
    Total Assets 162.384 122.558 128.573 149.289 158.579
    Property/Plant/Equipment, Total - Net 19.362 20.082 19.647 17.898 11.2
    Other Long Term Assets, Total 1.764 1.764 1.764 1.764 1.764
    Total Current Liabilities 35.066 32.357 29.715 31.395 29.269
    Accounts Payable 3.984 3.572 5.441 5.123 5.308
    Accrued Expenses 30.765 26.311 23.811 25.696 23.358
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 2.083
    Total Liabilities 154.531 119.471 118.862 113.91 112.35
    Total Long Term Debt 73.889 53.284 54.679 54.006 53.344
    Long Term Debt 73.889 53.284 54.679 54.006 53.344
    Other Liabilities, Total 45.576 33.83 34.468 28.509 29.737
    Total Equity 7.853 3.087 9.711 35.379 46.229
    Common Stock 0.008 0.008 0.008 0.008 0.008
    Additional Paid-In Capital 676.203 670.921 656.863 652.213 647.521
    Retained Earnings (Accumulated Deficit) -668.358 -667.842 -647.16 -616.842 -601.3
    Total Liabilities & Shareholders’ Equity 162.384 122.558 128.573 149.289 158.579
    Total Common Shares Outstanding 79.4121 79.2338 77.5166 77.2018 77.0104
    Other Current Liabilities, Total 0.317 0.391 0.463 0.576 0.603
    Property/Plant/Equipment, Total - Gross 35.176
    Accumulated Depreciation, Total -17.278
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -71.038 -6.553 -155.636 -86.372 -59.978
    Cash From Operating Activities -59.603 -65.55 -53.553 -77.578 -49.227
    Cash From Operating Activities 2.109 2.421 2.773 2.53 2.286
    Non-Cash Items 7.977 -58.517 98.135 8.139 7.88
    Cash Interest Paid 2.147 1.932 2.354 2.298 1.515
    Changes in Working Capital 1.349 -2.901 1.175 -1.875 0.585
    Cash From Investing Activities -3.715 -1.194 -0.841 -2.238 -1.889
    Capital Expenditures -3.715 -1.194 -0.841 -2.238 -1.889
    Other Investing Cash Flow Items, Total 0 0
    Cash From Financing Activities 1.454 2.851 228.014 75.341 68.64
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 1.454 3.296 228.014 38.066 62.265
    Issuance (Retirement) of Debt, Net 0 -0.445 0 37.275 6.375
    Net Change in Cash -61.864 -63.893 173.62 -4.475 17.524
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -30.318 -71.038 -55.496 -31.308 -12.542
    Cash From Operating Activities -19.973 -59.603 -42.645 -29.476 -18.6
    Cash From Operating Activities 0.483 2.109 1.618 1.109 0.557
    Non-Cash Items 12.362 7.977 7.749 1.152 -1.561
    Cash Interest Paid 0.701 2.147 1.521 0.99 0.495
    Changes in Working Capital -2.5 1.349 3.484 -0.429 -5.054
    Cash From Investing Activities -3.379 -3.715 -1.565 -0.771 -0.276
    Capital Expenditures -3.379 -3.715 -1.565 -0.771 -0.276
    Cash From Financing Activities 0.078 1.454 0.996 0.622 0.129
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 0.078 1.454 0.996 0.622 0.129
    Issuance (Retirement) of Debt, Net 0 0 0 0 0
    Net Change in Cash -23.274 -61.864 -43.214 -29.625 -18.747
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Summer Road, LLC Investment Advisor/Hedge Fund 7.7119 6122089 0 2023-06-30 LOW
    Opaleye Management Inc. Hedge Fund 7.281 5780000 -325900 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.9798 4747088 253121 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.1053 4052827 11437 2023-06-30 LOW
    Sawhney (Amarpreet) Individual Investor 4.0106 3183841 3183841 2023-03-31
    Millennium Management LLC Hedge Fund 3.0193 2396840 1360285 2023-06-30 HIGH
    Deltec Asset Management, LLC Investment Advisor/Hedge Fund 2.5972 2061797 87000 2023-09-30 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.9855 1576213 83254 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9776 1569904 112164 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 1.5743 1249751 -276521 2023-06-30 LOW
    Nuveen LLC Pension Fund 1.1584 919602 726569 2023-06-30 LOW
    Sectoral Asset Management Inc. Investment Advisor/Hedge Fund 1.0111 802680 802680 2023-06-30 MED
    D. E. Shaw & Co., L.P. Hedge Fund 0.8265 656105 -443665 2023-06-30 MED
    Cormorant Asset Management, LP Hedge Fund 0.8125 645000 645000 2023-06-30 LOW
    Cetera Investment Advisers LLC Investment Advisor 0.77 611250 10100 2023-06-30 MED
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7497 595150 7352 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.6179 490500 -142324 2023-06-30 HIGH
    AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund 0.5982 474900 474900 2023-06-30 LOW
    Banco Santander SA Corporation 0.5007 397443 129554 2023-06-30 LOW
    Susquehanna International Group, LLP Investment Advisor 0.4731 375601 131022 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Ocular Therapeutix Inc Company profile

    About Ocular Therapeutix Inc

    Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Ocular Therapeutix Inc revenues increased from $17.4M to $43.5M. Net loss decreased 96% to $6.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of derivative liab. increase from $86.2M (expense) to $78.1M (income), Interest Expense decrease of 1% to $6.7M (expense).

    Industry: Pharmaceuticals (NEC)

    24 Crosby Drive
    BEDFORD
    MASSACHUSETTS 01730
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.68 Price
    +0.300% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    BTC/USD

    44,045.50 Price
    -1.270% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading